Találati lista | Tudóstér

001-es BibID:	BIBFORM115339
035-os BibID:	(WoS)001225328200001 (Scopus)85174452529
Első szerző:	Zanatta, Elisabetta
Cím:	Should we use nintedanib as early therapy in patients with SSc-ILD? / Zanatta Elisabetta, Moccaldi Beatrice, Szucs Gabriella, Spagnolo Paolo
Dátum:	2024
ISSN:	1568-9972
Megjegyzések:	Systemic sclerosis (SSc) is a heterogeneous autoimmune disease, where a significant proportion of patients develop interstitial lung disease (ILD), which is the major cause of mortality. In recent years, the diagnosis of SScILD has improved a lot, and caring rheumatologists, together with pulmonologists, regularly screen and follow the development and course of ILD. Considerable progress has also been made in the treatment of SSc-ILD based on several clinical trials. The recommendations for immunosuppressive treatment have been modified and supplemented with targeted agents (tocilizumab, rituximab), and antifibrotic drugs such as nintedanib registered as a new treatment for SSc-ILD. However, there are no clear recommendations regarding the start and timing of nintedanib treatment. A debate on the early introduction of nintenadib or not took place on the 7th edition of the International Congress on Controversies in Rheumatology and Autoimmunity (CORA) in March/2023, and this review summarizes the main arguments that were discussed in this session.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Autoimmunity Reviews. - 23 : 1 (2024), p. 1-4. -
További szerzők:	Moccaldi, Beatrice Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Spagnolo, Paolo
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: